- Home
- RENE vs VTYX Comparison
RENE vs VTYX Comparison
Compare RENE & VTYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RENE
- VTYX
- Stock Information
- Founded
- RENE 2021
- VTYX 2018
- Country
- RENE United States
- VTYX United States
- Employees
- RENE N/A
- VTYX N/A
- Industry
- RENE Blank Checks
- VTYX Medicinal Chemicals and Botanical Products
- Sector
- RENE Finance
- VTYX Health Care
- Exchange
- RENE Nasdaq
- VTYX Nasdaq
- Market Cap
- RENE 151.4M
- VTYX 154.9M
- IPO Year
- RENE 2022
- VTYX 2021
- Fundamental
- Price
- RENE $11.71
- VTYX $2.08
- Analyst Decision
- RENE
- VTYX Buy
- Analyst Count
- RENE 0
- VTYX 4
- Target Price
- RENE N/A
- VTYX $11.33
- AVG Volume (30 Days)
- RENE 4.1K
- VTYX 1.9M
- Earning Date
- RENE 01-01-0001
- VTYX 02-25-2025
- Dividend Yield
- RENE N/A
- VTYX N/A
- EPS Growth
- RENE 42.92
- VTYX N/A
- EPS
- RENE 0.43
- VTYX N/A
- Revenue
- RENE N/A
- VTYX N/A
- Revenue This Year
- RENE N/A
- VTYX N/A
- Revenue Next Year
- RENE N/A
- VTYX N/A
- P/E Ratio
- RENE $26.90
- VTYX N/A
- Revenue Growth
- RENE N/A
- VTYX N/A
- 52 Week Low
- RENE $11.01
- VTYX $1.67
- 52 Week High
- RENE $11.78
- VTYX $11.48
- Technical
- Relative Strength Index (RSI)
- RENE 56.27
- VTYX 45.64
- Support Level
- RENE $11.56
- VTYX $1.83
- Resistance Level
- RENE $11.70
- VTYX $2.61
- Average True Range (ATR)
- RENE 0.02
- VTYX 0.18
- MACD
- RENE -0.00
- VTYX -0.03
- Stochastic Oscillator
- RENE 68.18
- VTYX 32.26
About RENE Cartesian Growth Corporation II
Cartesian Growth Corp II is a blank check company.
About VTYX Ventyx Biosciences Inc.
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.